SUMMIT-NJ: Weekly Injectable for Chronic Weight Management

A 72-week, randomized, double-blind study evaluating a once-weekly GIP/GLP-1 receptor agonist in adults with obesity or overweight with weight-related comorbidities.

Key eligibility criteria

• Adults 18–75 years
• BMI ≥ 30, or ≥ 27 with comorbidity
• No prior bariatric surgery
• Not currently on weight-loss medication

Additional criteria apply. A full eligibility review is completed by our coordinators during pre-screening — you may still qualify even if you're unsure about a criterion.